ToceranibDiscontinued Pfizer Patent issues

• 产品号: T525500
• CAS号: 356068-94-5
• 分子式: C22H25FN4O2
• 分子量: 396.4579032

产品别名

• 标题: ToceranibDiscontinued Pfizer Patent issues
• IUPAC标准名: 5-{[(3Z)-5-fluoro-2-oxo-2,3-dihydro-1H-indol-3-ylidene]methyl}-2,4-dimethyl-N-[2-(pyrrolidin-1-yl)ethyl]-1H-pyrrole-3-carboxamide
• IUPAC传统名: 5-{[(3Z)-5-fluoro-2-oxo-1H-indol-3-ylidene]methyl}-2,4-dimethyl-N-[2-(pyrrolidin-1-yl)ethyl]-1H-pyrrole-3-carboxamide
• 别名: SU 11654; 5-[(Z)-(5-Fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-1H-pyrrole-3-carboxamide; PHA 291639; 5-(5-Fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic Acid (2-(Pyrrolidin-1-yl)ethyl)amide

产品登记号

• CAS号: 356068-94-5

产品详细信息

详细说明 (English)

Toceranib is a multitargeted indolinone receptor tyrosine kinase (RTK) inhibitor. Toceranib exhibited activity against a variety of spontaneous malignancies in canine such as mast cell tumors, mixed mammary carcinomas, soft tissue sarcomas, and multiple m

参考文献

• London, C.A. et al.: Clin. Cancer Res., 9, 2755 (2003)
• Zavodovskaya, R. et al.: Am. J. vVt. Res., 67, 633 (2003)
• Malone, E.K. et al.: Vet. Comp. Oncol., 8, 209 (2003)